Nevro Corp
(NYSE:NVRO)
$
5.08
-0.26 (-4.87%)
Market Cap: 189.40 Mil
Enterprise Value: 157.99 Mil
PE Ratio: 0
PB Ratio: 0.69
GF Score: 44/100 Nevro Corp at Morgan Stanley Global Healthcare Conference Transcript
Sep 11, 2023 / 04:55PM GMT
Release Date Price:
$20.16
(+1.05%)
Kallum L Titchmarsh
Morgan Stanley, Research Division - Research Associate
Thanks, everyone, for coming. We are here today with Nevro's CFO, Rod MacLeod. I am Kallum Titchmarsh, medical device analyst here at Morgan Stanley.
Before we get started with the Q&A, I just got to jump into the fund disclosures. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
So Rob, thanks so much for joining us.
Roderick H. MacLeod
Nevro Corp. - Senior VP & CFO
Great for having us.
Questions & Answers
Kallum L Titchmarsh
Morgan Stanley, Research Division - Research Associate
Obviously, Kevin can't be here today, unfortunately. But wanted to start off really asking, he's been in the job now CEO 5 months or so. What's changed since he's taken
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot